C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Hayashi, Tsuguru, Shibata, Michihiko, Oe, Shinji, Miyagawa, Koichiro, Honma, Yuichi, Harada, Masaru
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2020
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/
https://ncbi.nlm.nih.gov/pubmed/33351844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker